Table 1.
Characteristics of the Participants at Baseline in the Microbiologically Eligible Population.*
| Characteristic | Control (N = 768) | Rifapentine– Moxifloxacin (N = 791) |
Rifapentine (N = 784) | Total (N = 2343) |
|---|---|---|---|---|
| Male sex — no./total no. (%) | 544/768 (71) | 563/791 (71) | 563/784 (72) | 1670/2343 (71) |
| Median age (range) — yr | 30.9 (13.7–77.5) | 31.0 (14.6–72.5) | 31.0 (14.1–81.4) | 31.0 (13.7–81.4) |
| Age group — no./total no. (%) | ||||
| 12–17 yr | 19/768 (2) | 25/791 (3) | 19/784 (2) | 63/2343 (3) |
| 18–35 yr | 479/768 (62) | 486/791 (61) | 485/784 (62) | 1450/2343 (62) |
| >35 yr | 270/768 (35) | 280/791 (35) | 280/784 (36) | 830/2343 (35) |
| Race — no./total no. (%)† | ||||
| Asian | 86/765 (11) | 89/790 (11) | 93/783 (12) | 268/2338 (11) |
| Black | 553/765 (72) | 552/790 (70) | 571/783 (73) | 1676/2338 (72) |
| White | 15/765 (2) | 13/790 (2) | 8/783 (1) | 36/2338 (2) |
| Multiracial | 111/765 (15) | 136/790 (17) | 111/783 (14) | 358/2338 (15) |
| HIV positivity — no./total no. (%) | 64/768 (8) | 62/791 (8) | 68/784 (9) | 194/2343 (8) |
| Median CD4 count among those with HIV positivity (IQR) | 334 (249–485) | 346 (253–458) | 351 (221–437) | 344 (223–455) |
| Cavitation on chest radiography — no./total no. (%)‡ | ||||
| Absent | 206/768 (27) | 213/791 (27) | 206/784 (26) | 625/2343 (27) |
| <4 cm | 251/768 (33) | 277/791 (35) | 246/784 (31) | 774/2343 (33) |
| ≥4 cm | 307/768 (40) | 295/791 (37) | 327/784 (42) | 929/2343 (40) |
| Median body weight — kg | 52.0 | 53.0 | 53.3 | 53.1 |
| WHO smear grade — no./total no. (%)§¶ | ||||
| Negative | 21/766 (2.7) | 31/789 (3.9) | 36/782 (4.6) | 88/2337 (3.8) |
| Scanty or 1–9 acid-fast bacilli | 121/766 (15.8) | 147/789 (18.6) | 124/782 (15.9) | 392/2337 (16.8) |
| 1+ | 187/766 (24.4) | 168/789 (21.3) | 172/782 (22.0) | 527/2337 (22.6) |
| 2+ | 229/766 (29.9) | 228/789 (28.9) | 227/782 (29.0) | 684/2337 (29.3) |
| 3+ | 198/766 (25.8) | 209/789 (26.5) | 214/782 (27.4) | 621/2337 (26.6) |
| Positive smear, WHO scale not used§ | 10/766 (1.3) | 6/789 (0.8) | 9/782 (1.2) | 25/2337 (1.1) |
| Median body-mass index (range)‖ | 18.9 (12.8–45.2) | 19.0 (14.1–39.1) | 18.9 (13.4–35.4) | 18.9 (12.8–45.2) |
| Current smoker — no./total no. (%) | 196/768 (26) | 175/791 (22) | 200/784 (26) | 571/2343 (24) |
| Prior course of tuberculosis treatment — no./total no. (%) | 83/768 (11) | 97/791 (12) | 85/784 (11) | 265/2343 (11) |
The microbiologically eligible population included all the participants except those who had no evidence of Mycobacterium tuberculosis–positive cultures, who had tuberculosis that was resistant to isoniazid, rifampin, or fluoroquinolones, or who were enrolled in violation of the eligibility criteria. HIV denotes human immunodeficiency virus, and IQR interquartile range.
Race was reported by the trial participants; information about race was not available for 5 participants.
Cavity size refers to the aggregate diameter of all cavities.
Sputum smears were not available for 6 participants.
Sputum smears were graded according to the World Health Organization (WHO) classification, which provides different criteria for each grade depending on the type of microscopy and magnification used at the site laboratory.35
The body-mass index is the weight in kilograms divided by the square of the height in meters.